Quest Diagnostics (DGX) recently announced a collaboration with Ultima Genomics, the developer of the revolutionary new ultra-high throughput sequencing architecture. Through the collaboration, the companies aim to improve patient access, affordability and outcomes by expanding the use of highly accurate, cost-efficient and high-volume whole genome sequencing in fast-growth areas, such as solid-tumor minimal residual disease (MRD) testing.The latest development will significantly fortify Quest Diagnostics’ ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find s ...

Quest Diagnostics Inc. (DGX) recently acquired select assets of Steward Health Care System's outreach laboratory services business, which provided services to physicians and patients in Pennsylvania and Ohio. The transaction's financial specifics were kept under wraps.The agreement gives patients and doctors more access to cutting-edge, excellent-quality diagnostic information services.The latest development is likely to broaden Quest Diagnostics' laboratory services offering.More on AgreementQuest Diagnost ...

FREMONT, Calif & SECAUCUS, N.J.--(BUSINESS WIRE)--Ultima Genomics, a developer of a revolutionary new ultra-high throughput sequencing architecture, and Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services, today announced a collaboration involving Ultima’s next generation sequencing (NGS) technology in oncology and other clinical areas. The collaboration aims to improve patient access, affordability and outcomes by broadening the use of highly accurate, cost-ef ...

BALTIMORE, Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology's personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT's interventional, randomized phase II clinical trial (AFT-57) in patients with unresectable stage III non-small cell lung cancer (NSCLC). The AFT-57 clinical study is supported by G ...

Quest Diagnostics Inc. (DGX) is likely to grow in the coming quarters, backed by strength in the legacy base business. The company is gaining from collaborations with health plans, hospitals and physicians amid a broad return to care. However, a high debt level on the balance sheet and intense competition also raise concerns.In the past year, this Zacks Rank #3 (Hold) stock has declined 8.9% against the industry’s 9% growth and a 24.5% rise of the S&P 500 composite.The renowned provider of diagnostic inform ...

SECAUCUS, N.J., Dec. 21, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest market developments and trends during a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024, at 6:45 p.m. ...

Quest Diagnostics Inc. (NYSE:DGX) Q3 2023 Results Conference Call October 24, 2023 8:30 AM ET Company Participants Shawn Bevec - VP, IR Jim Davis - Chairman, President & CEO Sam Samad - CFO Conference Call Participants Ann Hynes - Mizuho Securities David Westenberg - Piper Sandler Kieran Ryan - Deutsche Bank Elizabeth Anderson - Evercore Kevin Caliendo - UBS Jack Meehan - Nephron Research Patrick Donnelly - Citi Erin Wright - Morgan Stanley Brian Tanquilut - Jefferies Lisa Gill - JP Morgan Operator Welcome ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated 500 Plaza Drive Indicate by check mark whether the registrant has submi ...

Quest Diagnostics, Inc. (NYSE:DGX) Q2 2023 Earnings Conference Call July 26, 2023 8:30 AM ET Company Participants Shawn Bevec - VP, IR James Davis - Chairman, CEO & President Sam Samad - EVP & CFO Conference Call Participants Jack Meehan - Nephron Research Elizabeth Anderson - Evercore ISI A.J. Rice - Crédit Suisse Lisa Gill - JPMorgan Chase & Co. Eric Coldwell - Robert W. Baird & Co. Philip Chickering - Deutsche Bank Brian Tanquilut - Jefferies Kevin Caliendo - UBS Patrick Donnelly - Citigroup Operator Wel ...